"Chimeric antigen receptor modified T cells" trang 1 - tải miễn phí từ tailieunhanh
Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy

Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy
10    52    0
Modulation of chimeric antigen receptor surface expression by a small molecule switch

Modulation of chimeric antigen receptor surface expression by a small molecule switch
9    86    0
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: A meta-analysis

The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: A meta-analysis
13    33    1
Distribution of chimeric antigen receptormodified T cells against CD19 in B-cell malignancies

Distribution of chimeric antigen receptormodified T cells against CD19 in B-cell malignancies
10    35    1
Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment

Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment
9    12    1
Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients

Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients
9    6    1
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
17    55    0
Activated iNKT cells enhance the antitumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

Activated iNKT cells enhance the antitumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer
10    49    1
Tuning the performance of CAR T cell immunotherapies

Tuning the performance of CAR T cell immunotherapies
7    114    0
Optimized DNA electroporation for primary human T cell engineering

Optimized DNA electroporation for primary human T cell engineering
9    93    0
Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice

Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice
13    42    1
Challenges of driving CD30-directed CAR-T cells to the clinic

Challenges of driving CD30-directed CAR-T cells to the clinic
8    43    1
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)

Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)
7    53    1
Humanized CD19 CAR-T cells in relapsed/ refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Humanized CD19 CAR-T cells in relapsed/ refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
8    18    1
Pre-clinical research on the application of CAR-T therapy in the treatment of acute lymphoblastic leukemia

Pre-clinical research on the application of CAR-T therapy in the treatment of acute lymphoblastic leukemia
11    1    1
Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
10    4    1
B7-H3 targeted CAR-T cells show highly efcient anti-tumor function against osteosarcoma both in vitro and in vivo

B7-H3 targeted CAR-T cells show highly efcient anti-tumor function against osteosarcoma both in vitro and in vivo
12    1    1
Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
8    8    1